Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.

dc.contributor.author	Thomas, William L Jr
dc.contributor.author	Ramos, Fernando
dc.contributor.author	Hospenthal, Duane R.
dc.date.accessioned	2016-10-25T22:55:24Z
dc.date.available	2016-10-25T22:55:24Z
dc.date.issued	2003-08
dc.description.abstract	Pegylated interferons have recently been approved for treatment of hepatitis C. The safety of these formulations is reported to be similar to that of non-pegylated interferon. We present two patients who experienced exacerbations of their liver disease following administration of pegylated interferon alfa-2b. Vigilant monitoring of patients treated with these new agents is recommended.
dc.identifier.issn	0017-8594
dc.identifier.pubmed	14533347
dc.identifier.uri	http://hdl.handle.net/10524/53615
dc.language.iso	eng
dc.subject.mesh	Aged
dc.subject.mesh	Antiviral Agents/adverse effects
dc.subject.mesh	Hepatitis C, Chronic/drug therapy
dc.subject.mesh	Humans
dc.subject.mesh	Interferon-alpha/adverse effects
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Polyethylene Glycols/adverse effects
dc.subject.mesh	Recombinant Proteins
dc.title	Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
dc.type	Article
dc.type.dcmi	Text
prism.number	8
prism.pagerange	163-4
prism.publicationname	Hawaii Medical Journal
prism.volume	62

Now showing 1 - 1 of 1